This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.

Inclusion Criteria:

• Patients must be female ≥18 years of age
• Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer that were treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
• Patients can be either alive or deceased at the time of medical record abstraction
• Patients should not have any objection that anonymized data will be collected and subjected to automated processing.

Exclusion Criteria:

• Patient that were given olaparib within a clinical trial

The patient population observed in this study must fulfil all of the following inclusion criteria:

• Patients must be female ≥18 years of age
• Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer that were treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
• Patients can be either alive or deceased at the time of medical record abstraction
• Patients should not have any objection that anonymized data will be collected and subjected to automated processing.